Zhejiang Aoxiang Pharmaceutical

Zhejiang Aoxiang Pharmaceutical is a prominent Chinese pharmaceutical company focused on the development and large-scale production of high-end Active Pharmaceutical Ingredients (APIs) and advanced intermediates. Founded in 2010 and headquartered in Linhai, the company has established a robust presence in therapeutic areas such as hepatology, respiratory medicine, and cardiovascular health. Aoxiang operates as a dual-model business, functioning both as a proprietary product manufacturer and a Contract Development and Manufacturing Organization (CDMO) for global partners. Their portfolio features significant products like Entecavir and Peramivir, which are manufactured under strict international GMP standards. The company is publicly listed on the Shanghai Stock Exchange and is recognized for its technical expertise in complex chemical synthesis and chiral technology. With a strong commitment to regulatory compliance, Aoxiang has successfully passed numerous inspections by the US FDA and other international health authorities.